Prostate cancer. Clinical practice guidelines in oncology.

Published on Jan 1, 2010in Journal of The National Comprehensive Cancer Network11.908
· DOI :10.6004/JNCCN.2010.0012
James L. Mohler73
Estimated H-index: 73
Robert R. Bahnson35
Estimated H-index: 35
+ 22 AuthorsPatrick C. Walsh148
Estimated H-index: 148
đź“– Papers frequently viewed together
11 Authors (Hans-Peter Schmid)
7 Authors (Axel Heidenreich, ..., F. Zattoni)
#4Laurent J. Salomon (French Institute of Health and Medical Research)H-Index: 34
Purpose To evaluate the incidence of high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical small acinar proliferation (ASAP) in an initial 21-core extended biopsy scheme and to determine the prostate cancer detection rate in the repeated biopsy.
#1Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc)H-Index: 58
#2Filomena MazzeoH-Index: 5
Last. Joseph KergerH-Index: 12
view all 16 authors...
Purpose To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer. Patients and Methods
Bone is the most common site for metastasis in cancer and is of particular clinical importance in breast and prostate cancers due to the prevalence of these diseases. Bone metastases result in considerable morbidity and complex demands on health care resources, affecting quality of life and independence over years rather than months. The bisphosphonates have been shown to reduce skeletal morbidity in multiple myeloma as well as a wide range of solid tumours affecting bone by 30–50%. Quite approp...
#1Dominik BertholdH-Index: 13
#2Gregory R. Pond (Johns Hopkins University)H-Index: 72
Last. Ian F. Tannock (Johns Hopkins University)H-Index: 51
view all 6 authors...
Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival. Me...
Abstract Context.—The past decade has brought major changes in prostate biopsy sampling, interpretation, and reporting. Objective.—To summarize current information on diagnostic decision making, Gleason grading, “atypical” diagnoses, and use of immunostaining. Data Sources.—Pertinent literature from 1985 to 2005 is reviewed, emphasizing recent findings. Conclusions.—Diagnosis begins by evaluating a focus of atypical single-cell layer lined acini according to the 3 minimal diagnostic criteria for...
#1Mehsati Herawi (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 21
#2Hillel KahaneH-Index: 15
Last. Jonathan I. Epstein (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 162
view all 4 authors...
Purpose: We determined the influence of the extent of needle biopsy sampling on the detection rate of cancer on first biopsy within 1 year following a diagnosis of HGPIN.Materials and Methods: We identified 791 patients with HGPIN on the initial biopsy who had a followup biopsy within 1 year of their diagnosis. The mean interval from diagnosis of HGPIN to re-biopsy was 4.6 months. In the initial biopsy with HGPIN, 323 men had 8 or more cores (median 10, range 8 to 26) and 332 men had 6 core biop...
#1Rajal B. Shah (UM: University of Michigan)H-Index: 68
#2Lakshmi P. Kunju (UM: University of Michigan)H-Index: 56
Last. Mark A. Rubin (Harvard University)H-Index: 161
view all 6 authors...
We evaluated the diagnostic usefulness of the 34βE12-p63 cocktail, compared with 34βE12 and p63 used alone, in 34 prostate needle biopsy (NBXs) and 3 transurethral resection specimens containing atypical glandular proliferations and in 18 NBXs containing unequivocal prostate carcinoma (PCa). Staining intensity; percentage of basal cells staining in benign, atypical, and malignant glands; number of benign glands lacking basal cell staining; and staining variance were analyzed. All NBXs with unequ...
#1Fred Saad (UdeM: Université de Montréal)H-Index: 103
#2Donald M. GleasonH-Index: 5
Last. Ming ZhengH-Index: 18
view all 10 authors...
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion every 3 weeks for 15 months) reduced the incidence of skeletal-related events (SREs) in men with hormone-refractory metastatic prostate cancer. Among 122 patients who completed a total of 24 months on study, fewer patients in the 4-mg zoledronic acid group than in the placebo group had at least one SRE (38% versus 49%, difference = -11.0%, 95% confidence interval [CI] = -20.2% to -1.3%; P = .028), a...
#1Maxwell V. Meng (UCSF: University of California, San Francisco)H-Index: 60
#2Joseph Franks (UCSF: University of California, San Francisco)H-Index: 4
Last. Katsuto Shinohara (UCSF: University of California, San Francisco)H-Index: 68
view all 4 authors...
Abstract We sought to determine the utility of adding apical anterior horn biopsies to systematic prostate sampling regimens in detecting cancer in men with measured prostate volume ≤50 cc. We reviewed the biopsy data of consecutive men referred for an abnormal digital rectal exam or PSA elevation ≥4.0 ng/mL. All of these patients underwent lesion directed biopsy as well as a systematic 12-core biopsy regimen consisting of the standard sextant, bilateral lateral mid- and lateral base-sites, and ...
Cited By915
#1Roxanne Toivanen (Peter MacCallum Cancer Centre)H-Index: 16
#2Laura H Porter (Monash University)H-Index: 9
Last. Renea A. Taylor (Peter MacCallum Cancer Centre)H-Index: 28
view all 6 authors...
Abstract null null The heterogeneity of prostate cancer is evident at clinical, morphological and molecular levels. To aid clinical decision making, a three-tiered system for risk stratification is used to designate low-, intermediate-, and high-risk of disease progression. Intermediate-risk prostate cancers are the most frequently diagnosed, and even with common diagnostic features, can exhibit vastly different clinical progression. Thus, improved risk stratification methods are needed to bette...
#1Alex Boye (University of Cape Coast)H-Index: 10
#2Imad AhmadH-Index: 2
Last. Haroon KhanH-Index: 37
view all 5 authors...
Tumor-to-stroma ratio (TSR) is a prognostic factor that expresses the relative amounts of tumor and intratumoral stroma. In this study, its clinical and molecular relevance was evaluated in prostate cancer (PCa). The feasibility of automated quantification was tested in digital scans of tissue microarrays containing 128 primary tumors from 72 PCa patients stained immunohistochemically for epithelial cell adhesion molecule (EpCAM), followed by validation in a cohort of 310 primary tumors from 209...
#1Yelin Mulati (PKU: Peking University)H-Index: 1
#2Yu Fan (PKU: Peking University)H-Index: 13
Last. Zhisong He (PKU: Peking University)H-Index: 19
view all 5 authors...
Introduction:Enzalutamide, apalutamide and darolutamide have all been approved by FDA to treat high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) since 2018 based on interim results of several phase III clinical trails. Final analysis of long-term overall survival (OS) and adverse events (AEs) results of these trials have been successively published recently. To help clinical practice to precisely select optimal treatment for high-risk nmCRPC patients, we performed a network m...
#1Dae-Hyun Kim (SNU: Seoul National University)H-Index: 2
#2Wonkook Han (DGIST: Daegu Gyeongbuk Institute of Science and Technology)
Last. Hak Jong Lee (SNU: Seoul National University)H-Index: 19
view all 4 authors...
Photoacoustic (PA) imaging is used widely in cancer diagnosis. However, the availability of PA agents has not made great progress due to the limitations of the one currently in use, porphyrin. Porphyrin–Micelle (PM), developed by synthesizing porphyrin and PEG-3.5k, confirmed the amplification of the PA agent signal, and added binding affinity in an LNCaP model by attaching prostate-specific membrane antigen PSMA. Compared to the previously used porphyrin, a superior signal was confirmed, and th...
#1Connor Esterwood (UM: University of Michigan)H-Index: 6
#1Marcio Covas Moschovas (CMU: Carnegie Mellon University)H-Index: 8
#2Seetharam Bhat (CMU: Carnegie Mellon University)H-Index: 5
Last. Vipul R. Patel (CMU: Carnegie Mellon University)H-Index: 54
view all 6 authors...
The field of robotic surgery continues to evolve and the advent of the single-port (SP) platform is another step toward the future. The SP platform is a new technology that has promising implications for urologic surgery. Since the Food and Drug Administration (FDA) cleared this platform in 2018, multiple urologic procedures have been described, with radical prostatectomy being the most common. This article aims to describe and illustrate the step-by-step technique of SP radical prostatectomy. W...
#4Hans-Peter Schmid (HSG: University of St. Gallen)H-Index: 17
As multiple different treatment options are available for prostate cancer (PCa) and YouTube is commonly used as a source for medical information, we performed a systematic and comparative assessment of available videos guiding patients on their choice for the optimal treatment. An independent search for surgical therapy or radiotherapy of PCa on YouTube was performed and the 40 most viewed videos of both groups were analyzed. The validated DISCERN questionnaire and PEMAT were utilized to evaluat...
#1Miguel A. Nava-Cabrera (UAEM: Universidad AutĂłnoma del Estado de MĂ©xico)H-Index: 1
#2Erika AzorĂ­n-Vega (Interactive Intelligence)H-Index: 9
Last. Liliana Aranda-Lara (UAEM: Universidad AutĂłnoma del Estado de MĂ©xico)H-Index: 7
view all 0 authors...
Abstract null null The recent use of prostate-specific membrane antigen as a biological target have improved the theragnostic approach to prostate and other types of cancer. Radiopharmaceuticals based on PSMA inhibitors radiolabeled with beta emitters as Lutetium-177 have demonstrated remarkable efficacy and safety, however, their clinical evaluation have also shown that therapeutic response of bone located metastases is poorer than that presented by soft tissue lesions. These observations condu...
#1Xiaowei Cao (YZU: Yangzhou University)H-Index: 10
#2Qilong Song (YZU: Yangzhou University)
Last. Li Li (Nanjing Medical University)
view all 6 authors...
An innovative surface-enhanced Raman spectroscopy and lateral flow assay (SERS-LFA) biosensor combined with aptamer recognition had been developed for the convenient, rapid, sensitive and accurate detection of thrombin and platelet-derived growth factor-BB (PDGF-BB) associated with prostate cancer simultaneously. During the biosensor operation, thrombin and PDGF-BB in the sample were recognized and combined by thiol-modified aptamers immobilized on Au-Ag hollow nanoparticles (Au-Ag HNPs) surface...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.